My latest Forbes column is now out: "Free Speech 1, FDA 0".
I discuss a breaking update to my earlier Forbes piece on drug company Amarin's fight to engage in free speech in the form of off-label marketing of one of its products.
Basically, Amarin wanted to give truthful medical information to doctors which would allow them to more effectively use one of their drugs in a way that was legal, but not FDA-approved. The FDA forbade Amarin from engaging in such speech, and Amarin sued the FDA.
This past Friday, Amarin won an important legal victory in federal court. Judge Paul Engelmayer came down firmly on the side of free speech.
For more details see the full text of, "Free Speech 1, FDA 0".
(Earlier Forbes piece, "Drug Company Amarin Stands Up For Free Speech Against FDA", 5/8/2015.)
Update: Related commentary from Alex Tabarrok, "FDA Loses Another Free Speech Case"